Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Raw Materials (2016 - 2021)

Historic Raw Materials for Guided Therapeutics (GTHP) over the last 8 years, with Q1 2021 value amounting to $1.3 million.

  • Guided Therapeutics' Raw Materials rose 6309.07% to $1.3 million in Q1 2021 from the same period last year, while for Mar 2021 it was $1.3 million, marking a year-over-year increase of 6309.07%. This contributed to the annual value of $1.3 million for FY2020, which is 6338.03% up from last year.
  • Latest data reveals that Guided Therapeutics reported Raw Materials of $1.3 million as of Q1 2021, which was up 6309.07% from $1.3 million recorded in Q4 2020.
  • In the past 5 years, Guided Therapeutics' Raw Materials registered a high of $1.3 million during Q1 2021, and its lowest value of $781000.0 during Q1 2019.
  • Moreover, its 5-year median value for Raw Materials was $789000.0 (2017), whereas its average is $844294.1.
  • As far as peak fluctuations go, Guided Therapeutics' Raw Materials plummeted by 777.26% in 2017, and later surged by 6338.03% in 2020.
  • Quarter analysis of 5 years shows Guided Therapeutics' Raw Materials stood at $789000.0 in 2017, then fell by 0.76% to $783000.0 in 2018, then dropped by 0.26% to $781000.0 in 2019, then soared by 63.38% to $1.3 million in 2020, then grew by 0.08% to $1.3 million in 2021.
  • Its last three reported values are $1.3 million in Q1 2021, $1.3 million for Q4 2020, and $782000.0 during Q3 2020.